Pharmachemie tamoxifen

Teva subsidiary receives full approval for generic tamoxifen 10 mg tablet May 31. AstraZeneca still has patent protection on the compound (Nolvadex) until Aug. 20, 2002, and litigation is pending. The approval reflects an April Washington, D.C. federal court decision vacating FDA's award of 180 days of generic exclusivity to Barr, which has marketed tamoxifen under a patent settlement with AstraZeneca since 1992 (1"The Pink Sheet" April 10, p. 3)